IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the release of MX-7™, its latest and most advanced rainbow SET® board. Designed for integration into the more than 200 ...

Masimo SET ® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled Accuracy and Reliability in More Than 100 ...

Masimo study finds less than 1% bias and no skin tone discrepancies in neonatal pulse oximetry accuracy. NeoPODS data shows reliable SpO2 readings with minimal hypoxemia cases across diverse newborn ...

CHICAGO & IRVINE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) and Masimo (Nasdaq: MASI) today announced a joint agreement to integrate Masimo Signal Extraction Technology® (SET®) pulse ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Masimo today announced the results of a prospective study published in the International Journal of Neonatal Screening in which researchers in Marrakesh, Morocco, conducted the first Moroccan study on ...

IRVINE, Calif.-- (BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today that RD SET ® sensors with Masimo Measure-through Motion and Low Perfusion™ SET ® pulse oximetry have received FDA clearance ...

Masimo’s NeoPODS study in critically ill newborns found its SET pulse oximetry technology delivered consistent accuracy across all skin tones, with less than 1% bias. The findings address longstanding ...

NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race ...

These promising results—from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population—add to previously published evidence of its strong ...

These promising results-from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population-add to previously published evidence of its strong ...